The total return over the past 12 months is -13.80% vs. +16.94% for the S&P 500. So far it's up -10.34% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (13.80%) | +20.15% | +0.60% | +13.41% | (2.79%) | (1.06%) |
| Total Return CAGR | (13.80%) | +20.15% | +0.60% | +13.41% | (2.79%) | (1.06%) |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Galectin Therapeutics Inc. (GALT)
| Year | Start price | End price | GALT Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $4.16 | $3.73 | (10.34%) | +14.51% | (24.85%) |
| 2025 | $1.29 | $4.16 | +222.48% | +17.72% | +204.76% |
| 2024 | $1.66 | $1.29 | (22.29%) | +24.89% | (47.18%) |
| 2023 | $1.13 | $1.66 | +46.90% | +26.19% | +20.71% |
| 2022 | $2.07 | $1.13 | (45.41%) | (18.17%) | (27.24%) |
| 2021 | $2.24 | $2.07 | (7.59%) | +28.74% | (36.33%) |
| 2020 | $2.86 | $2.24 | (21.68%) | +18.37% | (40.05%) |
| 2019 | $3.43 | $2.86 | (16.62%) | +31.22% | (47.84%) |
| 2018 | $3.34 | $3.43 | +2.69% | (4.56%) | +7.25% |
| 2017 | $0.98 | $3.34 | +240.89% | +21.70% | +219.19% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
